Examining the Effect of Tks5 Sh3 Domain Mutations on Invadopodia Localization and Development in Cancer Cells by NC DOCKS at Appalachian State University & Whitaker, Kelley
 
 
 
 
 
EXAMINING THE EFFECT OF TKS5 SH3 DOMAIN MUTATIONS ON INVADOPODIA 
LOCALIZATION AND DEVELOPMENT IN CANCER CELLS 
 
 
by 
 
Kelley Elizabeth Whitaker 
 
 
Honors Thesis 
 
Appalachian State University 
 
 
Submitted to The Honors College 
in partial fulfillment of the requirements for the degree of 
 
Bachelor of Science 
 
August, 2015 
 
 
 
Approved by: 
 
 
! ! ! ! ! ! ! ! ! !
Darren!Seals,!Ph.D.,!Thesis!Director!
 
 
 
! ! ! ! ! ! ! ! ! !
Nicholas!Kenny,!Ph.D.,!Second!Reader!
 
 
 
! ! ! ! ! ! ! ! ! !
Leslie!Sargent!Jones,!Ph.D.,!Director,!The!Honors!College!
 
 
! 2!
 
 
 
 
 
 
 
 
 
Copyright by Kelley Elizabeth Whitaker 2015 
All Rights Reserved 
! i!
 
 
 
ABSTRACT 
 
Examining the Effect of Tks5 Domain Mutations on Invadopodia Localization and 
Development in Cancer Cells 
 
Kelley Whitaker 
 
Honors Thesis Director: Dr. Darren Seals 
 
Metastasis, the process by which cancers spread from their site of origin to distant 
anatomic sites, accounts for about ninety percent of all cancer deaths. Metastasis occurs 
when cancer cells acquire the invasive behaviors necessary for breaching tissue boundaries. 
Invadopodia, actin-rich cell surface protrusions, stimulate metastasis by enabling adhesion, 
motility, and extracellular matrix remodeling by cancer cells. Src tyrosine kinase and its 
substrate Tks5 localize to invadopodia and regulate their development. Tks5 is composed of 
a PX domain followed by five SH3 domains. While the lipid-binding PX domain is essential 
for Tks5 dependent invadopodia localization and development, the five protein-binding SH3 
domains of Tks5 are less defined.  
Since the general function of an SH3 domain is to provide a binding site for 
polyproline motifs in other proteins, we hypothesize that mutations within the SH3 domains 
of Tks5 would block the protein-protein interactions necessary for invadopodia localization 
and/or development in cancer cells. To study the role of these Tks5 SH3 domain mutations in 
invadopodia development, constructs containing inactivating point mutations (tryptophan to 
alanine) in each SH3 domain were shuttled into the expression vector pcDNA3.  
Expression of wild-type and mutant Tks5 protein was confirmed in electroporated 
LNCaP prostate cancer cells. These Tks5 SH3 domain mutations showed variable effects on 
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invadopodia development in LNCaP cells, some of which accentuated and some of which 
inhibited the invadopodia-dependent matrix remodeling activity exerted by wild-type Tks5. 
These mutant Tks5 constructs are currently being used to determine localization in 
invadopodia-competent Src-transformed fibroblasts.  
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INTRODUCTION 
 
The War on Cancer 
 
 The National Cancer Act in 1971 marked a beginning in the war on cancer – a battle 
that seems to become more complicated with each diagnosis and scientific discovery (Burke 
2004).  The term “cancer” defines the many diseases that arise from mutations in cells that 
cause them to proliferate uncontrollably and to spread to other areas of the body.  
Approximately one in three women and one in two men will develop cancer in their lifetimes 
(Burke 2004).  In 2014 alone, there were approximately 1,665,540 new cancer diagnoses and 
585,720 cancer deaths, making it the second most common cause of death in the United 
States following heart disease (Siegel et al. 2014).  The battle against cancer has proved to be 
very complicated.  A main reason for this is that the pathway(s) to cancer development in 
each individual can vary greatly.  The tremendous heterogeneity in cancer causality makes it 
extremely problematic to target and to treat (Hanahan and Weinberg 2000).  There are, 
however, several hallmarks of cancer that are shared by most, if not all, cancers.  These 
include: sustaining proliferative signaling, evading growth suppressors, resisting cell death, 
enabling replicative immortality, inducing angiogenesis, activating invasion and metastasis, 
reprogramming energy metabolism, and evading immune destruction (Hanahan and 
Weinberg 2011). 
 Much cancer research and clinical care has been directed at the surgical removal, 
irradiation, and/or chemotherapeutic treatment of cancerous cells.  However, solid tumors, 
encompassing as much as one billion cells, are not the main cause of death among cancer 
patients (Burke 2004).  Over 90% of all cancer-associated deaths are the consequence of a 
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process called metastasis.  Metastasis is the result of cancer cells acquiring the invasive 
behavior necessary to breach tissue boundaries (Hannahan and Weinberg 2000).  Once in the 
blood stream or lymph vessels, these metastasizing cancer cells can spread throughout the 
body and colonize vital organs such as the bones, liver, lungs, and brain (Burke 2004), 
allowing for more advanced stages of cancer to develop. 
 
Relationship between Invadopodia, Src, Tks5, and Cancer 
 
 Podosomes and invadopodia are actin-rich cell surface protrusions that play a role in 
extracellular matrix remodeling and invasion (Murphy and Courtneidge, 2012) (Figure 1).  
The term podosome is used to characterize the structures of normal invasive cell types as 
regulated tissue invasion in the body is necessary for many biological processes including 
wound healing, organ development, immune system function, and inflammatory responses.  
The term invadopodia is used for the podosome-like invasive structures of cancer cells.  
Invadopodia enable invasion because they stimulate adhesion, motility, and extracellular 
matrix remodeling and degradation by cancer cells (Gimona et al. 2008).  It has been 
speculated that invadopodia drive cancer cell invasion in the context of tumor metastasis. 
 
Figure 1. Depiction of Invadopodia. Invadopodia are actin-rich cell surface protrusions that 
extend into the underlying extracellular matrix (ECM) and support ECM remodeling by 
cancer cells. 
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Invadopodia have been found in human cancer cell lines as well as Src-transformed 
fibroblasts (Murphy and Courtneidge, 2012).  Src, the first identified retroviral oncogene 
(Martin 2001), is a membrane-associated, non-receptor protein tyrosine kinase that has a role 
in some of the advanced stages of human cancers (Courtneidge et al. 2005).  Among other 
factors, Src tyrosine kinase and its substrate Tks5 localize to invadopodia and regulate their 
development, though how they accomplish this has not been fully defined.  Tks5 is an 
adaptor protein comprised of an amino terminal phox (PX) homology domain followed by 
five Src homology 3 (SH3) domains (Lock et al. 1998) (Figure 2).  The PX domain of Tks5  
 
 
 
 
Figure 2. Tks5 Modular Design. Tks5 is comprised of an amino-terminal PX domain 
followed by five SH3 domains. The organization of the domains within Tks5 is not shown to 
scale. 
 
is known to bind to phosphatidylinosidol-3-phosphate PtdIns(3)P and PtdIns(3,4)P2 (Abram 
et al. 2003; Oikawa et al. 2008).  Moreover, invadopodia formation is dependent upon this 
phosphoinositide-binding property of the PX domain (Abram et al. 2003; Oikawa et al. 
2008).  In Src-transformed fibroblasts, the PX domain is targeted to invadopodia, and this 
domain is both necessary and sufficient for the invadopodia localization of Tks5 (Abram et 
al. 2003; Oikawa et al. 2008).  Site-selective mutation or full deletion of the PX domain 
disables binding of Tks5 to membranes and presumably disables the formation of the Tks5-
containing membrane protein complex necessary for invadopodia development (Abram et al. 
2003; Courtneidge et al. 2005).   
 
PX# SH3######SH3# ####SH3# ##SH3######SH3
# #
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 Tks5 directly regulates matrix-remodeling invadopodia activity.  Silencing of Tks5 
with shRNAs disables the ability of Src-transformed fibroblasts to form invadopodia, 
degrade a gelatin matrix, and invade through a matrix barrier comprised of Matrigel (Seals et 
al. 2005).  Conversely, ectopic expression of wild-type Tks5 construct in the LNCaP prostate 
cancer cell line, a cell line that has low levels of Tks5 and does not form invadopodia, is 
sufficient to induce invadopodia-associated matrix remodeling and invasion activity (Burger 
et al. 2014).  In this study we evaluated the use of model Src-transformed fibroblasts and 
LNCaP cells to determine the role of Tks5 SH3 domain mutations in the development of 
invadopodia.  
 
 Tks5 SH3 Domains and Invadopodia Development 
 
 Tks5 has five, tandem SH3 domains (Figure 2).  In general, the primary function of 
SH3 domains is to mediate protein-protein interactions (Nguyen et al. 1998). These domains 
are comprised of two β sheets that contain three variable loops.  One of the loops contains 
two, adjacent aromatic tryptophan residues that renders the SH3 protein eligible for binding 
to polyproline motifs.  A point mutation at the first tryptophan residue is known to change 
the overall secondary structure of the SH3 domain and therefore inhibit protein-protein 
interactions (Tanaka et al. 1995).  Currently, the polyproline-containing proteins that may 
bind to Tks5 SH3 domains are largely unknown though there is evidence that Tks5 interacts 
with ADAMs family metalloproteinases, N-WASp, WIP, and F-actin.  Members of the 
ADAMs (a disintegrin and metalloproteinase) family (Weaver 2006) are known to interact 
with Tks5 (Abram et al. 2003).  Specifically, ADAMs 12, 15, and 19 interact with Tks5 and 
ADAM19 binds to the fifth SH3 domain (Abram et al. 2003).  There is also evidence 
supporting N-WASp (Neural Wiskott-Aldrich Syndrome Protein) binding to all five SH3 
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domains, WIP (WASP-interacting protein) binding to the third and fifth SH3 domains, and F-
actin binding to the fifth SH3 domain of Tks5 (Weaver 2006, Oikawa et al. 2008, García et 
al. 2012).  Disrupting the binding of N-WASp to the SH3 domains of Tks5 has been shown 
to decrease invadopodia formation (Oikawa et al. 2008).  WIP is known to localize to 
invadopodia, and a recent study found that there is a correlation between decreased levels of 
WIP expression in cancer patients and improved prognosis (García et al. 2012).  Using Tks5 
mutants that contain a predicted inactivating point mutation in each of the five SH3 domains 
may allow for a better understanding of the role of these domains in the ability of Tks5 to 
control cancer cell invasion and metastasis. 
 
Objectives 
 In this study, we proposed to further explore the function of the Tks5 SH3 domains in 
invadopodia development.  Tks5 constructs were generated harboring point mutations in each 
of the five SH3 domains of Tks5.  These constructs were then shuttled into the mammalian 
expression vector pcDNA3 to ensure robust, ectopic expression of Tks5.  Both wild-type and 
mutant Tks5 constructs were then introduced into LNCaP cells to determine their role in 
inducing invadopodia activity.  They were also introduced into Src-transformed fibroblasts to 
study their localization to invadopodia.  This included a determination of their proper cell 
staining conditions for identifying the localization of ectopic Tks5.  Together, these assays 
help to pinpoint which SH3 domains are important for invasive cancer phenotypes. 
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MATERIALS AND METHODS 
 
Cell Culture 
 
 LNCaP cells (ATCC) were cultured at 37°C and 5% CO2 in RPMI-1640 media 
(Thermo Scientific Hyclone, Logan, UT) formulated with 2.05 mM L-Glutamine, 110 mg/L 
sodium pyruvate, 10 mM HEPES and supplemented with 10% fetal bovine serum (FBS; 
Sigma-Aldrich, St. Louis, MO), and 1% penicillin/streptomycin.  The cells were routinely 
subcultured every 3-4 days at 1:6 dilution. 
 Src-transformed fibroblasts (hereafter Src3T3 cells) were cultured at 37°C and 5% 
CO2 in Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma-Aldrich, St. Louis, MO) 
formulated with 4500 mg glucose/L, 110 mg sodium pyruvate/L, 4 mM L-glutamine and 
supplemented with 10% FBS and 1% penicillin/streptomycin.  The cells were routinely 
subcultured every 2-3 days at 1:20 dilution. 
 
Cloning 
 
 Tks5 constructs harboring mutations in each of their respective SH3 domains had 
been previously generated in the mammalian expression vector pSGT. To generate constructs 
harboring these same mutations in the mammalian expression vector pcDNA3, we took 
advantage of the fact that a wild-type version of Tks5 already existed in this destination 
vector. Thus, small segments surrounding the mutant SH3 domains were cut from pSGT and 
used to replace the same segment in the wild-type Tks5 construct in pcDNA3 thereby 
converting wild-type Tks5 to each SH3 domain mutant (Figure 3A). Four mutant SH3 
domain constructs for each of the first 4 SH3 domains of Tks5 (M1, M2, M3, and M4) were 
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generated in this fashion. In brief, mutant Tks5 constructs were cut with BlpI and BstEII 
(M1, M2, and M3) or BstEII and BsrGI (M4), and following purification on 1% 
agarose/0.5XTBE gels (Qiagen #28704), were ligated to the compatible sites generated by 
restriction of pcDNA3 with the same enzymes (Figure 3B and 3C). Ligation reactions used 
T4 DNA ligase (400 units, New England BioLab, #M0202S) at a 3:1 molar ratio 
(insert:vector) at 16˚C for overnight. Ligations were then transformed by heat-shock into 
NEB5α cells (New England BioLabs, #C2987H) according to manufacturer guidelines. 
Putative positive transformants grew as ampicillin resistant colonies on LB plates after 
overnight culture, were mini-prepped (Qiagen, #28704), and then sent to GeneWiz for DNA 
sequencing analysis to confirm the successful cloning of the mutated Tks5 construct. All 
DNA samples were quantitated on a Nanodrop (NanoDrop 1000 Spectrophotometer) 
according to manufacturer guidelines.  
 
 
Figure 3. Cloning Strategies for Tks5 SH3 Domain Mutants. (A) Diagram depicting the 
general strategy for moving Tks5 mutations from pSGT to pcDNA3.  SV40 and CMV are 
promoters. (B and C) Cloning strategies involving the indicated restriction enzymes (BlpI 
and BstEII for M1, M2, and M3; BstEII and BsrGI for M4) were used to replace regions of 
wild-type Tks5 in pcDNA3 with similar regions from the mutant SH3 domain constructs of 
pSGT. 
 
 
 
 
 
 
m1 
pSGT 
wt+ 
pcDNA3 
SV40 CMV 
A B 
C 
PX SH3-A* (M1) SH3-C SH3-D SH3-E 
Restriction Enzyme 
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BstEII 
SH2-B 3
PX SH3-A SH3-B SH3-C SH3-E 
Restriction Enzyme 
BsrGI  
Restriction Enzyme 
BstEII 
SH3-D* 
(M4) 
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Sequencing 
 
Tks5 SH3 domain mutant constructs subcloned into the expression vector pcDNA3 
were verified by DNA sequencing using regional primers. DNA sequencing using the vector-
specific primer SP6 were used to verify the inclusion of a C-terminal myc tag in certain 
pcDNA3-Tks5 constructs. All sequencing reactions were carried out by GeneWiz where 
vector constructs (800 ng) were mixed with primers (25 pmol) in a final volume of 15µL 
according to company guidelines.  Primers used in this study are listed in Table I. 
 
Table I. Primers used in this study. 
Primer Application Sequence 
Asuprimer4 Forward primer for M1 and 
M2 sequencing  
5’- GAAGTCTTCCGGTTCTTTGAG -3’ 
Asuprimer5 Forward primer for M3 
sequencing  
5’- GAGAGGACCACATCCAAGCTA -3’ 
Asuprimer6 Forward primer for M4 
sequencing 
5’- AGGGCTCTAGGAGTGAGGACT -3’ 
SP6 Reverse primer for Myc tag 
sequencing 
5’- GATTAAGGTGACACTATAG -3’ 
 
 
Electroporation 
 
 LNCaP and Src3T3 cells (2 x 106) were mixed with pSGT or pcDNA3 mammalian 
expression vector constructs (3-8µg) and AmaxaTM Cell Line NucleofectorTM Kit R (Lonza, 
Basel, Switzerland) solution in a final volume of 100µL.  Electroporations were carried out 
using the AmaxaTM NucleofectorTM 2b (Lonza, Basel, Switzerland) programs T-009 
(LNCaPs cells) and X-001 (Src3T3 cells).  Following the electroporation, the cells recovered 
in pre-warmed media for 15-30 minutes.  Cells were then plated in 6- or 12-well plates 
containing uncoated glass coverslips and incubated at 37°C for 24-48 hours.  Src3T3 cells 
were incubated on glass coverslips for fluorescent microscopy studies.  
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Immunoblotting 
 
 Cell lysates were prepared from cells grown in 6-well culture plates under described 
culture conditions.  All plates were kept on ice and washed twice in 1.2µL of ice-cold 
phosphate-buffered saline (PBS) and 1mM sodium orthovanadate.  Cells were then lysed 
with 100µL of ice-cold 1% NP-40 lysis buffer composed of 20mM Hepes (pH=7), 110mM 
sodium chloride, 40mM sodium fluoride, 1% NP-40, 1mM sodium orthovanadate, and the 
following protease inhibitors: 10µg/mL aprotinin, 10µg/mL benzamidine, 10µg/mL 
leupeptin, 10µg/mL pepstatin, and 1mM PMSF.  The cells were then scraped from each dish 
with a Corning 3008 Cell Lifter, transferred to ice-cold microfuge tubes, vortexed for 5 
seconds, and incubated on ice for 10 minutes.  Lysates were then centrifuged at 10,000xg for 
10 minutes at 4°C to pellet cellular debris.  Supernatants were then transferred to new ice-
cold microfuge tubes and assayed directly for protein concentration using a detergent-
compatible protein assay kit (Bio-Rad) with bovine serum albumin (BSA) as a standard.  
Lysates were diluted in SDS loading buffer at a concentration of 0.5µg/µL or 1µg/µL and 
heated at 95°C for 5 minutes before being loaded on a 7.5% polyacrylamide gel and 
undergoing protein separation by SDS-PAGE.  The polyacrylamide gel was run on a 
PowerPacTM HC High-Current Power Supply (Bio-Rad) at 100V for 15 minutes and then 
150V for 60 minutes.  Proteins were then transferred from the polyacrylamide gel to 
nitrocellulose membranes using a Trans-Blot® SD Semi-Dry Transfer Cell (Bio-Rad) for 35 
minutes at 0.22 Amps.  All immunoblots were blocked in 5% dry milk and 0.5% BSA in PBS 
containing 0.1% Tween-20 (PBST) and 0.05% sodium azide (pH = 7) for 60 minutes.  
Primary antibodies were then applied to the membranes and incubated at 4°C overnight.  
Immunoblotting primary antibodies included:  Myc (1:1000; 9E10, VARI or 4A6, #05-724, 
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Millipore), GAPDH (1:1000; #sc-25778; Santa Cruz), and Tks5 (1:1000; #sc-31022; Santa 
Cruz) in 10% blocking solution containing 0.05% sodium azide.  After three 10 minute 
washes in PBST, the appropriate species-specific secondary antibody conjugated to 
horseradish peroxidase (1:1000 and 1:2000; NA931V and NA934; GE Healthcare) was 
applied to the membranes for a minimum of 30 minutes at room temperature.  Immunoblots 
were developed using a Western Lightning Plus Chemiluminescence reagent (Perkin Elmer) 
according to manufacturer’s guidelines and then imaged using a ChemiDoc imaging system 
(Bio-Rad). 
 
 
Microscopy 
 
 Cells were grown on glass cover slips in 12-well plates under described culture 
conditions. Coverslips were fixed in 1ml 3% formaldehyde (Electron Microscopy Sciences) 
in PBS for 10 minutes, washed three times in 1mL PBS, permeabilized in 1mL 0.4% Triton 
X-100 for 4 minutes, and then washed three times in 1mL PBS again.  Primary antibodies 
were used to detect the Myc epitope (1:333 and 1:1000; clone 9E10, VARI; clone 4A6, 
Millipore) in 5% donkey serum/PBS overnight at 4°C.  Coverslips were then washed three 
times in 1mL PBS before being incubated with the appropriate fluorescent-conjugated 
secondary antibody (1:1000 and 1:2000; AlexaFlour 594-anti-mouse; A21203; GE 
Healthcare) and AlexaFluor 488-conjugated phalloidin (1:200, AlexaFluor 488 Phalloidin; 
A12379; Life Technologies) in 5% donkey serum/PBS at room temperature for 45 minutes.  
After another three washes in 1mL PBS, the coverslips were mounted onto glass slides with 
ProLong Gold plus DAPI (P36941; Life Technologies). Coverslips were incubated overnight 
at room temperature before sealing with nail polish.  Images were captured with an Olympus 
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BX51 microscope equipped with a Retiga EXi Fast 1394 camera.  Image processing was 
conducted with Q-Capture Suite software version 2.9.13.  Images were captured at 100X 
magnification at exposure times of 197ms, 902ms, and 100ms for actin, myc, and nuclei 
respectively. 
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RESULTS 
 
 Previous research conducted in the laboratory of Dr. Seals has used Src-transformed 
fibroblast (Src3T3) and LNCaP prostate cancer cell lines to study the development and 
function of invadopodia.  Src3T3 cells make invadopodia via the ectopic expression of 
constitutively active chicken Src(Y527F) (Furmaniak-Kazmierczak et al. 2007).  They have 
high levels of endogenous Tks5 protein.  LNCaP cells have low levels of Tks5 and do not 
form invadopodia (Burger et al. 2014).  However, ectopic expression of a wild-type Tks5 
construct is sufficient to induce invadopodia formation and invadopodia-associated matrix 
remodeling activity (Burger et al. 2014).  Both cell lines are easily manipulated model 
systems for studying the processes necessary for invadopodia development. 
 
Subcloning of Tks5 SH3 Domain Mutants into the pcDNA3 Vector  
 
 Prior to studying the function of the five Tks5 SH3 domain mutant constructs, we 
first wanted to demonstrate sufficient expression in these model cancer cell lines.  First, the 
expression of wild-type murine Tks5 from either the pSGT vector (SV40 promoter) or 
pcDNA3 vector (CMV promoter) were compared following electroporation into LNCaP 
cells.  After 48 hours, it was found that pcDNA-Tks5 exhibited much greater expression than 
pSGT-Tks5 (Figure 4). This suggested that the pcDNA3 vector might be a better choice in 
studies of invadopodia development in this cell line.  
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Figure 4. Effect of Promoter on Ectopic Tks5 Expression in LNCaP Cells. Immunoblot 
analysis of the expression of wild-type Tks5 constructs from the mammalian expression 
vectors pSGT and pcDNA3 following electroporation into LNCaP cells.  GAPDH served as a 
loading control. 
 
Previous research in the Seals lab had generated tandem nucleotide substitutions in 
the coding regions for each of the SH3 domains of murine Tks5. However, these constructs 
were present in the pSGT vector. Based on the results of Figure 4, we therefore decided to 
shuttle these SH3 domain mutants into pcDNA3 to allow for more robust expression of Tks5 
in LNCaP prostate cancer cells (Figure 3). Different restriction enzymes were used to replace 
the wild-type Tks5 already present in the pcDNA3 vector with the mutated Tks5 constructs 
found originally in the pSGT vector.  For mutant SH3 domains 1-3 (M1-M3), restriction 
enzymes BlpI and BstEII were used, and for mutant SH3 domain 4 (M4), restriction enzymes 
BstEII and BsrGI were used (Figures 3).  Tks5 mutant SH3 domain 5 (M5) had already been 
generated in the pcDNA3 vector by prior researchers in the Seals lab. 
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 Successful cloning of the first four Tks5 SH3 domain mutants was confirmed after 
performing a sequence analysis using the regional Tks5 primers (Table I).  The nucleotide 
sequence of the wild-type Tks5 construct in pcDNA3 is designated by the sequence 
TGGTGG and encodes a pair of tryptophans (Figure 5).  Each SH3 domain construct (M1-
M4), however, demonstrated the successful acquisition of the tandem nucleotide substitutions 
(GCGTGG) that changed the first tryptophan to an alanine. 
 
Figure 5. Annotated Sequence Analysis of Tks5 SH3 Domain Mutants.  Shown are the 
DNA sequencing results for the four mutant constructs confirming the acquisition of the 
tryptophan (W) to alanine (A) substitutions.  Sequencing was performed by GeneWiz using 
regional Tks5 primers. 
 
 
Effect of SH3 Domain Mutants on Invadopodia Activity in LNCaP Cells 
 
The Tks5 SH3 domain mutants are currently being electroporated into LNCaP 
prostate cancer cells to explore any alterations in their invadopodia-associated matrix 
remodeling properties when compared to wild-type Tks5.  It was initially hypothesized that 
the single point mutation in each of the five SH3 domains would inactivate the domain that 
the mutation inhabits and that this would interfere with invadopodia development.  However, 
Tks5 SH3 domain mutants M1-M3 have all been found to degrade gelatin more than the 
wild-type Tks5, where as M4 and M5 have been found to degrade gelatin less (Daly and 
Nucleotide Sequence M1: … GAGAAGAACGAAAGCGGC        TTTGTGAGCACATCTGAA …!
Nucleotide Sequence wt: … GAGAAGAACGAAAGCGGC        TTTGTGAGCACATCTGAA …!
W  W!
TGGTGG!
GCGTGG!
Nucleotide Sequence M3: … GACAAGAACTCGGGTGGT        TACGTGCAGATCGGGGAG …!
Nucleotide Sequence wt: … GACAAGAACTCGGGTGGT        TACGTGCAGATCGGGGAG …!TGGTGG!
GCGTGG!
Nucleotide Sequence M2: … CGAAAGAACCTGGAAGGC        TACATCAGGTACCTCGGC …!
Nucleotide Sequence wt: … CGAAAGAACCTGGAAGGC        TACATCAGGTACCTCGGC …!TGGTGG!
GCGTGG!
Nucleotide Sequence M4: … GAGAAGGCGGTAAGTGGG        TACGTGAGGTTTGGGGAG …!
Nucleotide Sequence wt: … AGAAGGCGGTAAGTGGGG        TACGTGAGGTTTGGGGAG …!TGGTGG!
GCGTGG!
A  W!
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Seals, unpublished data).  The reason for these differences is the emphasis of another project 
in the Seals lab.  However, an immunoblot analysis has been used to confirm the expression 
of wild-type Tks5 and the five SH3 domain mutants (M1-M5) in these cells (Figure 6). 
 
Figure 6. Immunoblot Analysis of Tks5 Mutant Constructs. Tks5 constructs (wild-type, 
wt; SH3 domain mutants, M1-M5) were electroporated into LNCaP cells, and then analyzed 
48 hours later for Tks5 protein levels using either a Tks5 antibody or an antibody to the Myc 
epitope.  GAPDH served as a loading control 
 
 
Effect of SH3 Domain Mutants on the Localization of Tks5 in Src3T3 Cells 
 
 One hypothesis regarding the differential effects of Tks5 on invadopodia 
development in LNCaP cells is that the mutations in the SH3 domains will impact 
invadopodia localization.  To address this, we have used fluorescent microscopy to study 
Tks5 localization in model Src3T3 cells. One caveat to these studies is that model 
invadopodia-competent cell lines like Src3T3 cells have abundant endogenous Tks5 
expression. To study the localization of the mutant Tks5 constructs, we needed to use 
constructs that harbor epitope tags.  Past work in the Seals lab had generated such constructs 
with the Myc epitope added to the 3’ end of the coding sequence.  Thus, when Myc was 
stained with a specific fluorescent antibody, we could be sure we were localizing the mutant 
Tks5 constructs, not the endogenous protein. We first wanted to confirm the presence of the 
Myc tag in the wild-type and mutant Tks5 constructs from pcDNA3 used previously in the 
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invadopodia activity studies in LNCaP cells by performing immunoblot analysis and DNA 
sequencing.  By immunoblot analysis, Tks5 was clearly being expressed, but there was no 
ability to detect Tks5 with an antibody to the Myc epitope (Figure 6). Moreover, using the 
SP6 primer derived from vector sequences, DNA sequencing confirmed that the Tks5 
constructs in pcDNA3 did not have the Myc epitope (Figure 7).  
 
 
 
 
Figure 7. Determining the Presence of the Myc tag on Tks5 Constructs. All indicated 
Tks5 constructs were sequenced at the 3’ end of the insert using the vector-specific primer 
SP6.  Only the Tks5-myc construct in pcDNA3 contained the Myc epitope (green). TAA 
(red) is a stop codon.  Vector sequences from pcDNA3 are blue.  Nucleotides indicated by 
“N” are unidentified. The numbers following each construct, in parenthesis, represent their 
stock numbers within the Seals lab archives. 
 
 
 We further examined for the presence of the Myc epitope by analyzing Src3T3 cells 
electroporated with wild-type Tks5 constructs from pcDNA3 and pSGT that were known to 
contain this tag (Figure 8).  Both vectors demonstrated Tks5 expression at very similar levels 
using an antibody to the myc epitope.  The Tks5-myc in the pcDNA3 vector also showed a 
light band slightly above the darker band that is in both pcDNA3 and pSGT lanes.  It is 
unknown what the lighter band represents. 
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Figure 8. Immunoblot Analysis of Tks5-myc Constructs. Tks5-myc constructs from 
pcDNA3 and pSGT vectors were electroporated into Src3T3 cells and protein levels were 
analyzed by immunoblot analysis using an antibody to the Myc tag. Comparable protein 
levels are shown for Tks5-myc in both of these vectors, though a lighter band at higher 
molecular weight (*) can also be seen in the pcDNA3 construct.  GAPDH served as a loading 
control.  
 
 In order to prepare for the localization experiments using the Tks5 SH3 domain 
mutant constructs, we first determined proper staining conditions using Src3T3 cells with or 
without electroporation of wild-type Tks5-myc.  Both cells were stained with and without 
phalloidin to visualize F-actin, with and without a primary myc antibody (1:333), with a 
mouse-specific secondary antibody (1:1000), and with DAPI to visualize nuclei.  The 
secondary antibody controls with and without phalloidin (Figure 9, panels A-F and panels M-
R) verified that the signal we see in the red channel of the microscope when staining with the 
primary Myc antibody (Figure 9, panels G-L and panels S-X) was not due to non-specific 
binding by the secondary antibody or from bleed-through of F-actin staining in the green 
channel.  Use of the Myc antibody increased the signal in the red channel of the Src3T3 cells 
electroporated with Tks5-myc as expected (Figure 9, panels H and K).  Signal was present 
throughout the cytoplasm of the cells, but also appeared to be strong in actin-rich 
invadopodia (arrows).  However, we also detected significant signal with the Myc antibody 
in Src3T3 cells that were not electroporated with Tks5-myc (Figure 9, panels T and W).  
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However, it does appear that the localization was confined to the cytoplasm with few 
invadopodia detected. 
 
 
Figure 9. Localization of Tks5-myc in Src3T3 Cells. Tks5-myc Src3T3 cells and Src3T3 
cells were stained under four different conditions: with and without AlexaFluor 488-
phalloidin (1:200) and with and without a primary Myc antibody (4A6; 1:333).  All 
conditions were stained with a secondary antibody (AlexaFlour 594-anti-mouse; 1:1000).  
Images were taken at 100X magnification. 
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DISCUSSION 
 
 In this study, attempts were made to ascertain the role of SH3 domain mutants in the 
localization of Tks5 to invadopodia and the impact of Tks5 on invadopodia activity.  To 
identify a role for Tks5 in invadopodia activity, mutant SH3 domain constructs in the pSGT 
vector were shuttled over to the pcDNA3 vector because the latter provided much better 
expression in LNCaP cells.  The successful cloning of the SH3 domain mutants M1-M4 was 
verified by DNA sequencing, while the expression of these mutants in the LNCaP prostate 
cancer cell line was verified by immunoblot analysis.  At this point, preliminary data 
suggests differential effects by the SH3 domain mutants on the ability of LNCaP cells to 
degrade gelatin monolayers, a measure of invadopodia-associated invasion.  It was initially 
hypothesized that an inactivating point mutation in one of the SH3 domains would lessen the 
invasive behavior of the LNCaP prostate cancer cells relative to wild-type Tks5.  It was 
shown, however, that Tks5 mutants M1-M3 accentuated gelatin degradation whereas mutants 
M4 and M5 inhibited gelatin degradation (Daly and Seals, unpublished data).  The reason for 
the variable change in the invasive qualities of the LNCaP cells is unknown.  One thought is 
that the change in protein interactions in the mutated Tks5 constructs can alter the ability of 
Tks5 to be phosphorylated by Src, and hence Tks5 activity.  This could lead to smaller or 
larger concentrations of Tks5 being phosphorylated in cells and therefore a change in the 
amount of active Tks5 in the cells.  Further studies will address this hypothesis.  
 The primary focus of this study was to address the localization of Tks5 in 
invadopodia-competent Src3T3 cells.  Unfortunately, Src3T3 cells, like many other model 
cell lines that are able to form invadopodia, have an abundance of endogenous Tks5.  We 
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initially thought that we could use the same constructs used in the invadopodia activity 
assays described above because they harbored a Myc epitope tag on the 3’ end of the coding 
sequence.  However, both immunoblot analysis and DNA sequencing confirmed the absence 
of this epitope in the pcDNA3 constructs.  It is thought that the pSGT constructs do contain 
the Myc epitope tag, thus we have thus turned to the pSGT constructs for these localization 
studies.   
 To study the localization of mutated Tks5 constructs in Src3T3 cells, proper staining 
conditions must be established using wild-type, Myc-tagged Tks5.  To this end, Src3T3 cells 
electroporated with pSGT Tks5-myc were cultured on glass coverslips and then stained with 
fluorescently-conjugated phalloidin, a myc antibody, a fluorescent conjugated secondary 
antibody, and DAPI to stain for actin, myc, and nuclei respectively.  Src3T3 cells without 
Tks5-myc were also cultured on glass coverslips and stained using the same conditions as a 
control.  The staining of the Tks5-myc Src3T3 cells gave good signals.  Phalloidin stained 
the actin filaments and revealed numerous punctate and rosette-shaped invadopodia.  Myc 
could also be seen in the cells, mostly in the cytoplasm, but there was also signal in the 
invadopodia as well.  It is known that Tks5 localizes to invadopodia, so seeing the Myc 
signal there was expected. 
 Control Src3T3 cells were similarly stained with phalloidin and the Myc antibody and 
gave similar signals as the Src3T3 cells electroporated with Tks5-myc.  This was unexpected, 
and suggests that the Myc antibody may need further titration.  However, we did note that 
there was less invadopodia staining by the Myc antibody in the control cells versus the cells 
that were elctroporated with Tks5-myc.  Further efforts are needed to verify expression of 
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these constructs in these cells and in the development of the best staining conditions to reveal 
localization of ectopic Tks5. 
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FUTURE DIRECTIONS 
 
 Determining where each Tks5 SH3 domain mutant localizes to in invadopodia-
competent Src3T3 cells will help clarify the role of Tks5 in invadopodia development as well 
as the ability of cancer cells to invade and metastasize.  This work, alongside gelatin 
degradation assays and assays of invasion and Tks5 phosphorylation will determine how 
active the mutated Tks5 is in these cancer cells, which would bring to light the role of Tks5 
in tumors as well. 
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